ImmuPharma, the AIM-quoted drug developer behind the P140 autoimmune platform and the Kapiglucagon diabetes programme, appeared among the most volatile UK stocks on 23 September 2026. Fresh interim results, a share-price-linked funding arrangement and a targeted P140 licensing deal give traders several reasons to watch.

ImmuPharma plc (LSE:IMM) was among the most volatile UK stocks on 23 September 2026. The company's shares trade on AIM, the London Stock Exchange's growth market.

ImmuPharma is a small drug discovery and development Business with two main assets: P140, a peptide platform for autoimmune disease, and Kapiglucagon, a glucagon prodrug being developed for type 1 diabetes. Its interim results on 15 September 2026 arrived alongside two scientific updates, and management reiterated its aim of securing a commercial deal for P140 during 2026. With funding partly tied to the share price through a sharing agreement, the stock can be sensitive to sentiment.

Why ImmuPharma (IMM) Is in Focus

The immediate trigger is IMM's appearance among the most volatile UK stocks on 23 September 2026, a measure of the size of recent price moves rather than their direction.

The timing follows a busy September. On 15 September 2026, ImmuPharma published interim results, announced an international Patent filing for P140 and highlighted a peer-reviewed publication reporting P140 activity in a preclinical model of metabolic dysfunction-associated steatohepatitis (MASH). A major shareholding notification from Lanstead Capital Investors followed on 10 September. For a company whose value rests on clinical and partnering milestones, news like this can drive sharp moves.

What Does ImmuPharma Do?

P140 is designed to modulate the immune system in autoimmune conditions. It was previously developed as Lupuzor for lupus, and US company Avion Pharmaceuticals is a partner. ImmuPharma is also developing a companion diagnostic intended to identify patients most likely to respond, and the P140 international patent filing relates to this precision-medicine approach.

Kapiglucagon is a prodrug designed to overcome glucagon's instability in solution, with potential use in dual-hormone artificial pancreas systems. ImmuPharma is evaluating the US Food and Drug Administration's 505(b)(2) pathway, which can allow reliance on existing data for an approved active ingredient. Neither product is approved or generating revenue.

What Has Been Happening Recently?

On 17 March 2026, ImmuPharma announced a fundraise of up to £7.5 million: a £6.0 million subscription by Lanstead at 6.0p per share and a retail offer of up to £1.5 million. The issue price was a 13.7% discount to the 6.95p closing mid-price on 16 March. Shareholders approved the resolutions at a general meeting on 7 April 2026, and the company later reported total gross proceeds of £6.47 million, including about £0.47 million from retail investors.

Kapiglucagon moved into execution. ImmuPharma announced IND-enabling activities on 5 May 2026, appointed Bachem as active ingredient manufacturer on 25 June, named Thermo Fisher Scientific as drug product Manufacturing partner on 22 July and selected Kymos Group for bioanalytical work on 10 August.

On P140, a University of Murcia publication on glioblastoma research appeared on 24 June, and the MASH publication and patent filing followed on 15 September. All AGM resolutions were approved on 25 June 2026.

What Are the Numbers Saying?

For the six months to 30 June 2026, the operating loss was £1.1 million, against £1.2 million a year earlier. Research and Development spending was £0.6 million and administrative expenses £0.4 million.

The reported loss rose to £4.7 million from £1.9 million, which the company attributed mainly to a £3.36 million Revaluation of a derivative financial asset. Cash at 30 June 2026 was £0.7 million, and the company said it expects a cash runway into the second half of 2028.

For 2025 as a whole, ImmuPharma reported a loss of £1.8 million, compared with £2.5 million in 2024, and year-end cash of £1.4 million.

Why Is the Share Price Attracting Attention?

The facts: IMM appeared among the most volatile UK stocks on 23 September 2026. Under the Lanstead sharing agreement, £6.0 million of subscription proceeds are settled in monthly instalments over 20 months, with each payment adjusted up or down depending on the share price against an 8.0p benchmark. The company is targeting a P140 commercial deal in 2026.

Possible interpretations: One possible interpretation is that the sharing agreement makes the share price itself relevant to how much cash ImmuPharma ultimately receives, which some traders may watch closely. The derivative revaluation in the interims shows how that link can affect reported numbers. Some investors may also be positioning around the possibility of a P140 deal, although no agreement has been announced. Others may simply see a small-cap biotech where scientific publications and thin trading can amplify moves in either direction.

How Does the FTSE AIM All-Share Context Matter?

ImmuPharma is quoted on AIM, and this article has not verified whether it is a constituent of the FTSE AIM All-Share index. The index is best treated as a backdrop: it tracks a broad range of AIM companies, many of them early-stage and loss-making, where sentiment towards risk can shift quickly.

Pre-revenue biotech stocks on AIM often trade on news flow, financing terms and partnering expectations rather than earnings. There is no evidence that movements in AIM indices caused IMM's recent volatility; company-specific announcements appear more relevant.

What Could Investors Watch Next?

Items that could influence sentiment include:

  • P140 partnering: whether ImmuPharma concludes the commercial deal it has targeted for 2026.
  • Kapiglucagon regulatory steps: progress towards a pre-IND meeting with the FDA and the IND-enabling programme.
  • Sharing agreement settlements: monthly Lanstead payments, which vary with the share price.
  • P140 patents: progress on the international PCT application and UK patent examination.
  • Shareholder notifications: further holding disclosures from major investors, such as the 10 September 2026 Lanstead notice.

The Bottom Line

ImmuPharma appeared among the most volatile UK stocks on 23 September 2026 after a run of announcements, including interim results, a P140 patent filing and new preclinical data. The AIM-quoted company narrowed its operating loss in the first half, but a derivative revaluation pushed its reported loss to £4.7 million, and cash stood at £0.7 million at the end of June. Its funding partly depends on the share price through the Lanstead sharing agreement, which adds a layer of sensitivity. What matters next is whether the targeted P140 licensing deal materialises in 2026, how Kapiglucagon progresses towards the FDA, and how the sharing agreement settles over the coming months.